Loading…
Sectoral / Thematic · UTI Mutual Fund · AMFI code 100806UTI - Healthcare Fund
Disclosed for 95 months, Jul 2017 to Sep 2026.
Portfolio value
₹452 Cr
down ₹23 Cr vs Aug 2018
- Stocks held
- 23
- down 2 vs Aug 2018
- Top 10 weight
- 67.7%
- of the portfolio in its ten largest
- Cash & debt
- 3.1%
- cash, money market and debt
- Moves this month
- 0 in · 2 out
- added to 7, trimmed 15
UTI - Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In September 2018 it disclosed 23 stocks worth ₹452 Cr, down ₹23 Cr from Aug 2018. Its largest positions were Sun Pharmaceutical Industries Limited (10.0%), Zydus Lifesciences Limited (9.9%), Cipla Limited (8.7%); the ten largest together made up 67.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 84.7% of its equity. Cash and debt stood at 3.1%. Compared with Aug 2018 the fund entered 0 new stocks and exited 2.
Against 229 other Sectoral / Thematic funds
Concentration
93%
Top-10 weight is higher than 93% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
45%
Holds more cash than 45% of peers
What these mean: concentration · cash
Holdings in September 2018
Download CSVEvery line the fund disclosed, with the change against Aug 2018. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 10.04% | up 0.03 pts | ₹45.4 Cr | down ₹2.2 Cr | Trimmed |
| Zydus Lifesciences Limited | 9.87% | up 1.17 pts | ₹44.6 Cr | up ₹3.3 Cr | Added |
| Cipla Limited | 8.68% | down 0.18 pts | ₹39.3 Cr | down ₹2.9 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 6.87% | down 0.30 pts | ₹31.1 Cr | down ₹3 Cr | Trimmed |
| Sanofi India Limited | 6.56% | up 0.22 pts | ₹29.7 Cr | down ₹45 L | Trimmed |
| IPCA Laboratories Limited | 6.29% | up 0.18 pts | ₹28.5 Cr | down ₹57 L | Trimmed |
| Pfizer Limited | 5.45% | down 0.84 pts | ₹24.7 Cr | down ₹5.2 Cr | Trimmed |
| Divi's Laboratories Limited | 4.81% | up 0.25 pts | ₹21.7 Cr | up ₹8 L | Held |
| Alkem Laboratories Limited | 4.75% | up 0.10 pts | ₹21.5 Cr | down ₹63 L | Trimmed |
| Ajanta Pharma Limited | 4.43% | down 0.61 pts | ₹20 Cr | down ₹3.9 Cr | Trimmed |
| Aurobindo Pharma Limited | 3.50% | up 0.31 pts | ₹15.8 Cr | up ₹67 L | Added |
| Dr. Reddy's Laboratories Limited | 3.48% | up 0.22 pts | ₹15.8 Cr | up ₹24 L | Added |
| Thyrocare Technologies Limited | 3.17% | up 0.55 pts | ₹14.4 Cr | up ₹1.9 Cr | Added |
| Cash, TREPS & receivables | 3.11% | up 0.28 pts | ₹14.1 Cr | up ₹59 L | Added |
| Lupin Limited | 3.00% | up 0.05 pts | ₹13.6 Cr | down ₹46 L | Trimmed |
| Max India Limited | 2.65% | down 0.01 pts | ₹12 Cr | down ₹67 L | Trimmed |
| FDC Limited | 2.36% | down 0.30 pts | ₹10.7 Cr | down ₹2 Cr | Trimmed |
| Syngene International Limited | 2.20% | up 0.13 pts | ₹10 Cr | up ₹10 L | Added |
| Dr. Lal Path Labs Limited | 2.12% | up 0.39 pts | ₹9.6 Cr | up ₹1.3 Cr | Added |
| Strides Pharma Science Limited | 2.04% | up 0.32 pts | ₹9.2 Cr | up ₹1 Cr | Added |
| Narayana Hrudayalaya Limited | 1.80% | up 0.04 pts | ₹8.2 Cr | down ₹24 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 1.00% | down 0.11 pts | ₹4.5 Cr | down ₹77 L | Trimmed |
| Shilpa Medicare Limited | 0.97% | down 0.18 pts | ₹4.4 Cr | down ₹1.1 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 0.83% | down 0.07 pts | ₹3.8 Cr | down ₹51 L | Trimmed |
What changed, Aug 2018 to Sep 2018
New New positions (0)
None.
Exited Exited (2)
- Indoco Remedies Limitedwas 1.5% · ₹7.2 Cr
- Unichem Laboratories Limitedwas 0.1% · ₹50 L
Added Biggest additions
- Zydus Lifesciences Limitedup ₹3.3 Cr (+1.17% pts)
- Thyrocare Technologies Limitedup ₹1.9 Cr (+0.55% pts)
- Dr. Lal Path Labs Limitedup ₹1.3 Cr (+0.39% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Aug 2018, the weight rose most in Healthcare Services (+1.1 pts) and Pharmaceuticals & Biotechnology (+0.3 pts), and fell most in Pharmaceuticals (−1.3 pts).
- Healthcare Services12.1% → 13.2%+1.1 pts
- Pharmaceuticals & Biotechnology84.4% → 84.7%+0.3 pts
- Pharmaceuticals3.4% → 2.1%−1.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Sep 2017 | Mar 2018 | Jun 2018 | Aug 2018 | Sep 2018 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.1% | 76.5% | 84.3% | 84.4% | 84.7% |
| Healthcare Services | 10.5% | 9.5% | 9.4% | 12.1% | 13.2% |
| Pharmaceuticals | 14.2% | 10.6% | 6.3% | 3.4% | 2.1% |
Allocation in Sep 2018change vs Aug 2018
- Pharmaceuticals & Biotechnology (16)84.7%▲ 0.3 pts
- Healthcare Services (6)13.2%▲ 1.1 pts
- Pharmaceuticals (1)2.1%▼ 1.3 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2018
3.1%
▲ 0.3 pts vs Aug 2018
- Cash alone
- 3.1%
- cash and net receivables
- A year earlier
- 4.9%
- Sep 2017 · now ▼ 1.8 pts
- Last 12 months
- 1.5% – 3.7%
- lowest to highest · record 7.3% in Jul 2017
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.